Status:
COMPLETED
Aldara for the Treatment of Large and/or Multiple sBCC
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Conditions:
Carcinoma, Basal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
BCC is the most common form of skin cancer. Current treatment is often surgery but this can be limited by the number of lesions, their location the age of the patient or the potential cosmetic outcome...
Eligibility Criteria
Inclusion
- One or more sBCC on torso, neck or face
- Total surface area \<= 40 sq cm
Exclusion
- Pregnancy or women who are breastfeeding
- Xeroderma pigmentosum, albinism, epidermodysplasia verruciformis, any genetic anomaly accompanied by skin tumors
- Metatypical, adnexal, or sclerodermiform carcinomas
- Current or other previous malignant skin tumor (epidermoid carcinoma, melanoma) in the region of the current lesion
- Known HIV positive serology
- Skin tumor that is already or highly likely to become metastatic
- Presence of a clinically significant anomaly or illness (immunological, cardiovascular, pulmonary, hematological, neurological, hepatic, renal, endocrine, gastrointestinal, collagenous)
- Previous organ transplant history
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00189280
Start Date
May 1 2003
End Date
October 1 2007
Last Update
February 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de DermatologieHôpital Dupuytren
Limoges, France, 87042